, Volume 12, Issue 6, pp 352-354
Date: 01 Sep 2010

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Robak T, Dmoszynska A, Solal-Celigny P, et al.: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1756–1765.

Rating

•Of importance.

Introduction

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the United States [1]. There has been considerable progress in understanding the biology and treatment of CLL in last 20 years. The introduction of purine analogs (pentostatin, fludarabine, and cladribine) dramatically increased the response rates compared to alkylating agents [2, 3]. Combination chemoimmunotherapy has further improved the overall frequency of response to over 80% in treatment-naïve and over 60% in relapsed/refractory disease, respectively [47].

The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has been demonstrated to be one of the most effective regimens in younger patients with ...